Patents by Inventor Isabel Masip
Isabel Masip has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9040701Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: GrantFiled: July 29, 2010Date of Patent: May 26, 2015Assignee: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Peypoch, Alejandra Moure Fernández, Daniel González Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García Villar, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Patent number: 8871787Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders.Type: GrantFiled: February 8, 2013Date of Patent: October 28, 2014Assignee: Laboratorios Salvat, S.A.Inventors: Juan Lorenzo Catena Ruiz, José Hildalgo Rodríguez, María del Carmen Serra Comas, Isabel Masip Masip
-
Patent number: 8785430Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.Type: GrantFiled: July 23, 2012Date of Patent: July 22, 2014Assignee: Consejo Superior de Investigaciones CientificasInventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypooh, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León, Maria Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria
-
Publication number: 20140051721Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.Type: ApplicationFiled: February 8, 2013Publication date: February 20, 2014Applicant: LABORATORIOS SALVAT, S.A.Inventors: Juan Lorenzo CATENA RUIZ, José HILDALGO RODRÍGUEZ, María del Carmen SERRA COMAS, Isabel MASIP MASIP
-
Patent number: 8492402Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders.Type: GrantFiled: November 26, 2008Date of Patent: July 23, 2013Assignee: Laboratorios Salvat, S.A.Inventors: Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, María del Carmen Serra Comas, Isabel Masip Masip
-
Patent number: 8252786Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.Type: GrantFiled: March 7, 2007Date of Patent: August 28, 2012Assignee: Consejo Superior de Investigaciones CientificasInventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, legal representative, Ma Carmen Fabrega Claveria, legal representative, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León
-
Publication number: 20120122868Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: ApplicationFiled: July 29, 2010Publication date: May 17, 2012Applicant: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Pyepoch, Alejandra Moure Fernández, Daniel Gonzáles Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Publication number: 20110207769Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.Type: ApplicationFiled: November 26, 2008Publication date: August 25, 2011Applicant: LABORATORIOS SALVAT, S.A.Inventors: Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Maria del Carmen Serra Comas, Isabel Masip Masip
-
Publication number: 20110160189Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.Type: ApplicationFiled: March 7, 2007Publication date: June 30, 2011Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Angel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León
-
Patent number: 7838534Abstract: Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema wherein: R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl; R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 is (CH2)1-4—COR4 or (CH2)1-4—S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl; n is 0, 1 or 2; X? is a pharmaceutically acceptable anion.Type: GrantFiled: July 25, 2007Date of Patent: November 23, 2010Assignee: Chiesi Farmaceutici S.p.A.Inventors: Gabriele Amari, Andrea Rizzi, Riccardo Patacchini, Valentina Cenacchi, Gino Villetti, Juan Lorenzo Catena Ruiz, Isabel Masip Masip
-
Publication number: 20100075984Abstract: Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(?O)— or —NHC(?S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical of a cycle; R4 represents —H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent —H or halogen, and R7 represents —H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans.Type: ApplicationFiled: January 18, 2007Publication date: March 25, 2010Applicant: LABORATORIOS SALVAT, S.A.Inventors: José Hidalgo Rodríguez, Juan Lorenzo Catena Ruiz, Isabel Masip Masip, Maria del Carmen Serra Comas, Oscar Rey Puiggrós, Carmen Lagunas Arnal, Carolina Salcedo Roca, Dolors Balsa López
-
Publication number: 20090088438Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: June 25, 2008Publication date: April 2, 2009Applicant: LABORATORIOS SALVAT, S.A.Inventors: Carmen SERRA COMAS, Anna FERNANDEZ SERRAT, Dolors BALSA LOPEZ, Isabel MASIP MASIP, Juan Lorenzo CATENA RUIZ, Jose HIDALGO RODRIGUEZ, Carmen LAGUNAS ARNAL, Carolina SALCEDO ROCA, Andres FERNANDEZ GARCIA
-
Patent number: 7423172Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)—B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: GrantFiled: July 29, 2005Date of Patent: September 9, 2008Assignee: Laboratorios Salvat, S.A.Inventors: Carmen Serra Comas, Anna Fernández Serrat, Dolors Balsa López, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernández García
-
Publication number: 20080039493Abstract: Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema wherein: R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl; R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 is (CH2)1-4—COR4 or (CH2)14—S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl; n is 0, 1 or 2; X? is a pharmaceutically acceptable anion.Type: ApplicationFiled: July 25, 2007Publication date: February 14, 2008Inventors: Gabriele Amari, Andrea Rizzi, Riccardo Patacchini, Valentina Cenacchi, Gino Villetti, Juan Catena Ruiz, Isabel Masip Masip
-
Publication number: 20070276043Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: July 29, 2005Publication date: November 29, 2007Inventors: Carmen Serra Comas, Anna Fernandez Serrat, Dolors Balsa Lopez, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, Jose Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
-
Publication number: 20060229255Abstract: N-alkylglycine trimers with the capacity to arrest the cell cycle in human cancer cells and to induce apoptosis useful for the therapy of cancer. Combination of said N-alkylglycine trimers with taxol.Type: ApplicationFiled: April 8, 2004Publication date: October 12, 2006Inventors: Gema Tarrason, Claudia Cases, Jaume Piulats, Angel Messeguer, Nuria Cortes, Isabel Masip